Salas Dolores, Vanaclocha Mercedes, Ibáñez Josefa, Molina-Barceló Ana, Hernández Vicente, Cubiella Joaquín, Zubizarreta Raquel, Andreu Montserrat, Hernández Cristina, Pérez-Riquelme Francisco, Cruzado José, Carballo Fernando, Bujanda Luis, Sarasqueta Cristina, Portillo Isabel, de la Vega-Prieto Mariola, Morillas Juan Diego, Valentín Vicente, Lanas Angel, Quintero Enrique, Castells Antoni
General Directorate Public Health, Avda. Calatuña, 21, 46020, Valencia, Spain,
Cancer Causes Control. 2014 Aug;25(8):985-97. doi: 10.1007/s10552-014-0398-y. Epub 2014 May 24.
To compare two strategies for colorectal cancer screening: one-time colonoscopy versus fecal immunochemical testing (FIT) (and colonoscopy for positive) every 2 years, in order to determine which strategy provides the highest participation and detection rates in groups of sex and age.
This analysis was performed with data from the first screening round within the COLONPREV study, a population-based, multicenter, nationwide trial carried out in Spain. Several logistic regression models were applied to identify the influence of the screening test on participation rates and detection of proximal and distal neoplasms, as well to identify the influence of age and sex: women aged 50-59 years, women aged 60-69 years, men aged 50-59 years, and men aged 60-69 years.
Participation was higher in women than in men, especially among women aged 50-59 years (25.91 % for colonoscopy and 35.81 % for FIT). Crossover from colonoscopy to FIT was higher among women than men, especially among those aged 60-69 years (30.37 %). In general, detection of any neoplasm and advanced adenoma was higher with colonoscopy than with FIT, but no significant differences were found between the two strategies for colorectal cancer detection. Detection of advanced adenoma in both arms was lower in women [specifically in women aged 50-59 years (OR 0.31; 95 % CI 0.25-0.38) than in men aged 60-69 years]. Women aged 50-59 years in the colonoscopy arm had a higher probability of detection of advanced adenoma (OR 4.49; 95 % CI 3.18-6.35), as well as of detection of neoplasms in proximal and distal locations (proximal OR 19.34; 95 % CI 12.07-31.00; distal OR 11.04; 95 % CI 8.13-15.01) than women of the same age in the FIT arm. These differences were also observed in the remaining groups but to a lesser extent.
Women were more likely to participate in a FIT-based strategy, especially those aged 50-59 years. The likelihood of detection of any neoplasm was higher in the colonoscopy arm for all the population groups studied, especially in women aged 50-59 years. Distinct population groups should be informed of the benefits of each screening strategy so that they may take informed decisions.
比较两种结直肠癌筛查策略:一次性结肠镜检查与每两年进行一次粪便免疫化学检测(FIT)(检测呈阳性者再进行结肠镜检查),以确定哪种策略在不同性别和年龄组中具有最高的参与率和检出率。
本分析使用了COLONPREV研究首轮筛查的数据,该研究是在西班牙开展的一项基于人群的多中心全国性试验。应用多个逻辑回归模型来确定筛查试验对参与率以及近端和远端肿瘤检出的影响,同时确定年龄和性别的影响:50 - 59岁女性、60 - 69岁女性、50 - 59岁男性以及60 - 69岁男性。
女性的参与率高于男性,尤其是在50 - 59岁的女性中(结肠镜检查为25.91%,FIT为35.81%)。从结肠镜检查转为FIT的女性比例高于男性,尤其是在60 - 69岁的女性中(30.37%)。总体而言,结肠镜检查对任何肿瘤和高级别腺瘤的检出率高于FIT,但在两种结直肠癌检测策略之间未发现显著差异。在两个组中,女性高级别腺瘤的检出率较低[特别是50 - 59岁的女性(OR 0.31;95% CI 0.25 - 0.38)低于60 - 69岁的男性]。结肠镜检查组中50 - 59岁的女性比FIT组中同年龄的女性有更高的高级别腺瘤检出概率(OR 4.49;95% CI 3.18 - 6.35),以及近端和远端肿瘤的检出概率(近端OR 19.34;95% CI 12.07 - 31.00;远端OR 11.04;95% CI 8.13 - 15.01)。在其他组中也观察到了这些差异,但程度较小。
女性更有可能参与基于FIT的筛查策略,尤其是50 - 59岁的女性。在所有研究的人群组中,结肠镜检查组中任何肿瘤的检出可能性更高,尤其是在50 - 59岁的女性中。应向不同人群告知每种筛查策略的益处,以便他们能够做出明智的决策。